A Single Ascending Dose Study Assessing the Safety, Tolerability, PK and PD of MYK-491

Status:
Completed

Trial end date:
2017-11-28

Target enrollment:

Participant gender:

Up to 72 healthy volunteers will be given a single dose of MYK-491 or placebo and be monitored for safety and tolerability over a 7 day period.

Phase 1

MyoKardia, Inc.